3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Dermatologic
1
Conditions
Leukemia
4
Rectal Neoplasms
3
Lymphoma, Large B-Cell, Diffuse
3
Leukemia, Lymphocytic, Chronic, B-Cell
3
Colorectal Neoplasms
3
Colonic Neoplasms
3
Waldenstrom Macroglobulinemia
2
Small Cell Lung Carcinoma
2
Prostatic Neoplasms
2
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Neoplasms, Plasma Cell
2
Neoplasms
2
Multiple Myeloma
2
Melanoma
2
Lymphoma, Mantle-Cell
2
Lymphoma, Follicular
2
Lung Neoplasms
2
Leukemia, Myeloid, Acute
2
Carcinoma, Renal Cell
2
Wilms Tumor
1
Urinary Bladder Neoplasms
1
Unspecified Adult Solid Tumor, Protocol Specific
1
Squamous Cell Carcinoma of Head and Neck
1
Solid Tumors
1
Skin Neoplasms
1
Ovarian Neoplasms
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Large-Cell, Immunoblastic
1
Lymphoma, B-Cell, Marginal Zone
1
Lymphoma
1
Interventions
aldesleukin
9
Interleukin-2
9
Nivolumab
7
fludarabine phosphate
6
Dacarbazine
6
Cyclophosphamide
6
fludarabine
5
Temozolomide
4
Ipilimumab
4
Fluorouracil
4
montanide ISA 51
3
Surveys and Questionnaires
3
Semaxinib
3
Radiotherapy
3
Radiation
3
Mohs Surgery
3
Educational Status
3
Cisplatin
3
Allovectin-7
3
zanolimumab
2
talabostat
2
sonidegib
2
poly ICLC
2
binimetinib
2
Whole-Body Irradiation
2
Vinblastine
2
Vemurafenib
2
Tacrolimus
2
Tablets
2
Surgical Procedures, Operative
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Skin Neoplasms
×
oblimersen
×
Clear all
NCT00518895
2011-11-07
AGENDA
Genta Incorporated
Phase 3
Completed
300 enrolled